-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
.
On December 29, Yiling Pharmaceutical had a net outflow of 238 million yuan
According to the data, Yiling Pharmaceutical has always been guided by clinical needs and relied on the company's endogenous strong innovation strength to provide effective and economical drugs
.
R&D and innovation is the foundation of Ling's sustainable development, and the company has always insisted on maintaining real money investment
in the field of innovation and R&D.
.
R&D and innovation is the foundation of Ling's sustainable development, and the company has always insisted on maintaining real money investment
in the field of innovation and R&D.
The data shows that from 2016 to 2021, the R&D investment of Yiling Pharmaceutical was 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan and 838 million yuan, respectively, and the proportion of R&D investment to operating income exceeded 8%
for four consecutive years.
It is reported that in the past two years, a total of 15 new traditional Chinese medicine drugs have been approved for marketing in China, of which 3 are innovative Chinese medicines developed by Yiling Pharmaceutical, which is the largest number of enterprises
approved in the same period.
for four consecutive years.
It is reported that in the past two years, a total of 15 new traditional Chinese medicine drugs have been approved for marketing in China, of which 3 are innovative Chinese medicines developed by Yiling Pharmaceutical, which is the largest number of enterprises
approved in the same period.
On December 29, Zhongsheng Pharmaceutical had a net outflow of 146 million yuan
According to the data, Zhongsheng Pharmaceutical's products cover major diseases such
as ophthalmology, cardiovascular and cerebrovascular, and respiratory.
According to the third quarterly report of Zhongsheng Pharmaceutical in 2022, the company's main revenue was 1.
991 billion yuan, a year-on-year increase of 9.
19%; The net profit attributable to the parent was 249 million yuan, down 20.
73%
from the same period last year.
as ophthalmology, cardiovascular and cerebrovascular, and respiratory.
According to the third quarterly report of Zhongsheng Pharmaceutical in 2022, the company's main revenue was 1.
991 billion yuan, a year-on-year increase of 9.
19%; The net profit attributable to the parent was 249 million yuan, down 20.
73%
from the same period last year.
Proprietary Chinese medicine is the core business foundation of Zhongsheng Pharmaceutical, and the innovative drug pipeline is steadily advancing
.
The domestic study of influenza 1.
1 class new drug 1273 tablets is in phase III.
clinical studies, and some subjects have been enrolled, and it is expected that the enrollment of phase III clinical trials by the end of 2022 is expected to be completed
.
The US clinical trial has been approved and will be carried out
at an opportune time.
The phase I clinical trial of RAY1216 tablets has achieved the expected research purpose, and the phase II.
/III clinical study is expected to advance
rapidly.
.
The domestic study of influenza 1.
1 class new drug 1273 tablets is in phase III.
clinical studies, and some subjects have been enrolled, and it is expected that the enrollment of phase III clinical trials by the end of 2022 is expected to be completed
.
The US clinical trial has been approved and will be carried out
at an opportune time.
The phase I clinical trial of RAY1216 tablets has achieved the expected research purpose, and the phase II.
/III clinical study is expected to advance
rapidly.
Zhongsheng Pharmaceutical recently said on the interactive platform that the sales of the company's cold-related products have increased significantly recently, and some antipyretic and detoxification, antipyretic and analgesic, expectorant and cough products such as Zhongsheng pills, ibuprofen tablets, and dexcarbromethorphan tablets have been seriously insufficient
due to the sharp increase in market demand.
At the same time, in response to market demand, the production end has been fully loaded, and does its best to meet market demand
.
The Company is focusing its efforts and resources on advancing the RAY1216 Tablets randomized, double-blind, placebo-controlled Phase III clinical study, which is progressing well
.
due to the sharp increase in market demand.
At the same time, in response to market demand, the production end has been fully loaded, and does its best to meet market demand
.
The Company is focusing its efforts and resources on advancing the RAY1216 Tablets randomized, double-blind, placebo-controlled Phase III clinical study, which is progressing well
.
On December 29, Huahai Pharmaceutical had a net outflow of 120 million yuan
According to the data of the annual report, the company's R&D investment in 2021 reached a new high, exceeding 1 billion yuan, a year-on-year increase of more than 60%, mainly because the company's R&D investment in biological drugs, new drugs and generic drugs continued to increase
.
.
It is reported that the company's recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection is a recombinant fusion protein targeting vascular endothelial growth factor (VEGF), which is a class 1 new drug of Huahai Pharmaceutical on the golden track of ophthalmic drugs, and 4 indications have been approved for clinical trials
.
Huahai Pharmaceutical's layout in the field of anti-tumor drugs is not only in high-end generic drugs, but also in the class 1 new drugs currently under development, HB0030 injection, HB0025 injection, HOT-1030 injection, HB002.
1T injection, HB0028 injection and HB0036 are all aimed at advanced tumors
.
.
Huahai Pharmaceutical's layout in the field of anti-tumor drugs is not only in high-end generic drugs, but also in the class 1 new drugs currently under development, HB0030 injection, HB0025 injection, HOT-1030 injection, HB002.
1T injection, HB0028 injection and HB0036 are all aimed at advanced tumors
.
On December 29, China Pharmaceutical's net outflow was 116 million yuan
According to the data, in recent years, China Pharmaceutical has initially established an integrated industrial pattern of trade, industry, technology and clothing driven by international trade, supported by the pharmaceutical industry and linked by pharmaceutical commerce, and the industrial form involves planting and processing, research and development, production, sales, logistics, import and export trade, academic promotion, technical services and other industrial
chains.
At 09:25 on December 19, 2022, China Pharmaceutical rose to the limit, and the current transaction volume was 137 million yuan
.
In terms of data, China Pharmaceutical has risen by 33.
15% in the past 3 days and 26.
80%
in the past 5 days.
chains.
At 09:25 on December 19, 2022, China Pharmaceutical rose to the limit, and the current transaction volume was 137 million yuan
.
In terms of data, China Pharmaceutical has risen by 33.
15% in the past 3 days and 26.
80%
in the past 5 days.
Fundamentally, from January to June 2022, the composition of China's pharmaceutical operating income was: pharmaceutical business accounted for 71.
45%, pharmaceutical trade accounted for 20.
49%, chemical preparations accounted for 5.
74%, APIs accounted for 2.
43%, proprietary Chinese medicines accounted for 1.
43%, and internal offset accounted for -1.
89%.
In terms of finance, the operating income of China National Pharmaceutical in the first three quarters of 2022 was 26.
917 billion yuan, a year-on-year increase of 0.
71%.
The net profit attributable to the parent was 767 million yuan, a year-on-year decrease of 8.
25%.
45%, pharmaceutical trade accounted for 20.
49%, chemical preparations accounted for 5.
74%, APIs accounted for 2.
43%, proprietary Chinese medicines accounted for 1.
43%, and internal offset accounted for -1.
89%.
In terms of finance, the operating income of China National Pharmaceutical in the first three quarters of 2022 was 26.
917 billion yuan, a year-on-year increase of 0.
71%.
The net profit attributable to the parent was 767 million yuan, a year-on-year decrease of 8.
25%.
On December 29, Jiuan Medical had a net outflow of 106 million yuan
Jiuan Medical iHealth kit products are in strong demand in the US market, and the company achieved revenue of 24.
589 billion yuan in the first three quarters of this year, a year-on-year increase of 3010.
77%; the net profit attributable to the parent was 16.
050 billion yuan, a year-on-year increase of 31918.
64%; The non-net profit attributable to the parent deduction was 16.
232 billion yuan, a year-on-year increase of 65616.
92%.
589 billion yuan in the first three quarters of this year, a year-on-year increase of 3010.
77%; the net profit attributable to the parent was 16.
050 billion yuan, a year-on-year increase of 31918.
64%; The non-net profit attributable to the parent deduction was 16.
232 billion yuan, a year-on-year increase of 65616.
92%.
It is reported that at present, the new model of diabetes diagnosis and care "O+O" of Jiuan Medical has been implemented in about 50 cities and more than 230 hospitals across the country
.
The model is in the accelerated phase, and the company plans to open about 600 care centers across the country in the next three to four years to form a professional diabetes care management system
.
.
The model is in the accelerated phase, and the company plans to open about 600 care centers across the country in the next three to four years to form a professional diabetes care management system
.
In addition, Jiuan Medical said on the investor interactive platform on December 28 that the recent increase in oximeter sales, the company is also paying attention to market changes, making every effort to ensure the orderly progress of production, and strive to meet market demand
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). .
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
